Active surveillance for nonmuscle invasive bladder cancer
نویسندگان
چکیده
منابع مشابه
Active surveillance for nonmuscle invasive bladder cancer
Nonmuscle invasive bladder cancer (NMIBC) is known to be a heterogeneous malignancy that requires varying treatment modalities and follow-up schedules. Low-grade Ta papillary tumors are categorized as low-risk NMIBC because of their favorable prognosis. There is an expanding movement that overdiagnosis and overtreatment should be avoided considering the economic impact and the patients' quality...
متن کاملNonmuscle-invasive and Muscle-invasive Urinary Bladder Cancer
This study compared the imaging quality, diagnostic accuracy, and apparent diffusion coefficient (ADC) values of reduced field-of-view (rFOV) diffusion-weighted imaging (DWI) and full field-of-view (fFOV) single-shot echo-planar imaging with regard to patients with nonmuscle-invasive or muscle-invasive bladder cancer.Thirty-nine patients with 60 bladder tumors underwent rFOV and fFOV DWI in thi...
متن کاملPreclinical evaluation of VAX-IP for nonmuscle invasive bladder cancer
INTRODUCTION Bladder cancer is the second most common urothelial carcinoma worldwide, the sixth leading cause of cancer death, and the fourth most common malignancy of men in developed countries.1 An estimated 70% of bladder cancer patients present with nonmuscle invasive disease (NMIBC), with tumors confined to the mucosal surface of the uroepithelium (Ta), tumors invading the lamina propria b...
متن کاملEmerging intravesical therapies for management of nonmuscle invasive bladder cancer
Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients present with superficial or nonmuscle invasive bladder cancer (NMIBC). Intravesical bacillus Calmette-Guerin (BCG) is the most effective agent for preventing disease recurrence, and the only therapy able to inhibit disease progression. However, recurrence rates as high as 30% and significant loc...
متن کاملNonmuscle invasive bladder cancer: a primer on immunotherapy
Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibod...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Investigative and Clinical Urology
سال: 2016
ISSN: 2466-0493,2466-054X
DOI: 10.4111/icu.2016.57.s1.s4